This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs), or Discontinuation Due to Adverse Events (AEs)
Timeframe: Week 4 to Week 8
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Week 4.
Timeframe: Week 4
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Week 8.
Timeframe: Week 8
Change From Baseline in Heart Rate at Week 4.
Timeframe: Week 4
Change From Baseline in Heart Rate at Week 8.
Timeframe: Week 8
Change From Baseline in Weight at Week 4.
Timeframe: Week 4
Change From Baseline in Weight at Week 8.
Timeframe: Week 8